PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc. This CE activity for ANCC and AANP credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

PROGRAM OVERVIEW

In order for patients with pulmonary arterial hypertension (PAH) to have the best outcomes, early diagnosis and treatment are necessary to avoid irreversible pathologic changes. Unfortunately, about 20% of patients with PAH exhibit symptoms for over 2 years before a diagnosis is made. In addition, studies also show racial discrepancies between outcomes specific to PAH in addition to more general findings concerning race, ethnicity, and socioeconomic status discrepancies concerning life expectancy, and access to insurance. This program will highlight how racial/ethnic disparities in PAH impact delayed diagnosis, treatment, and other health outcomes. To avoid irreversible damage and select the best treatment plan based on the individual patient profile, regular risk assessment and application of the guidelines are necessary. This activity will present guideline-based recommendations on the diagnosis and treatment of PAH as well as well as a patient case study.

FACULTY

Martha Kingman, DNP, APRN, FNP-C Family Nurse Practitioner Pulmonary Hypertension Clinic University of Texas Southwestern Medical Center Dallas, Texas

Release date: August 31, 2022 Expiration date: August 31, 2023 Estimated time to complete activity: 60 minutes

TARGET AUDIENCE

This educational initiative is designed for nurse practitioners, advance practice nurses, physicians, and physician assistants who work in primary care and manage patients with or at risk for PAH.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Outline the latest PAH guidelines regarding early diagnosis and initiation of therapy, while taking into consideration how racial and ethnic disparities may play into treatment delays and patient outcomes
Describe a guideline-directed, evidence-based management plan for PAH that includes consideration of current guidelines, combination therapies, escalation strategies and current clinical trial data and patient-characteristics
Discuss how to incorporate patient-focused management tactics to address racial and ethnic disparities and the practical considerations of patients with PAH

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 31, 2022 through August 31, 2023, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour (which includes 0.1 hour of pharmacology). Nursing Continuing Education Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. Physician Continuing Education

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com. For information about AANP or ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. and Global Education Group, requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity: Martha Kingman, FNP-C, DNP Advisor: United Therapeutics Consultant: Aerovate Consultant/Advisor: Acceleron/Merck, Bayer, Gossamer Bio, Johnson & Johnson/Janssen, Liquidia, The following project managers/planners: Olivia Benevento, Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Liddy Knight, Rhys Williams, RN, MSN, FNP, Kristin Delisi, NP, Michelle Rizzo, ELS, and Patima Tanapat, PhD reported that they have no financial relationships or relationships to products or devices with ineligible companies related to the content of this CE activity.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Understanding the Role of Early Diagnosis and Treatment in PAH in the Context of Racial and Ethnic Disparities: Nurse Practitioners on the Frontlines of Care